GREY:SBIYF - Post by User
Comment by
Everswanon Jun 18, 2009 11:42pm
419 Views
Post# 16083089
RE: 1 yr of cash at quite a cost
RE: 1 yr of cash at quite a costOperational plant based insulin is still a theory.
Not proven still that is it 30% cheaper to make.
SBS does have convincing arguments.
Hydresia scale up is indicative of how cheap it can be but you have all these polish and indian companies making cheap insulin.
New drugs to reduce insulin usage have also got or will get FDA approval so exponential explosion of insulin demand could be tampered.
Also, Partners are a bit scare of FDA approval for Plant based insulin. It will be the first bioequivalent approval. Like them, I would rather wait for more FDA clarity before committing to a formal approval.
The last question is why the heck did Mannkind back down? Mannkind subsequently decided to buy a bacteria based production line for a mere 3.6 millions.
For me, the best catalyst for this company Hydresia. If they can turn a decent profit from that business and reduce burn rate to nothing or turn it positive. We have a winner here.
The big plus is that they are survival this financial crisis.
i will probably load up later this year or in 2010...